Tricyclic compounds

Patent metadata

Field	Value
Publication number	US-11820773-B2
Application number	US-202117456106-A
Country	US
Kind code	B2
Filing date	Nov 22, 2021
Priority date	Nov 24, 2020
Publication date	Nov 21, 2023
Grant date	Nov 21, 2023

Abstract

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

First claim

What is claimed is:

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, having the structure:

wherein:
X is CH, CD, CF, C(CH 3 ) or N;
R 1 is a 3,4-substituted phenyl substituted with two moieties independently selected from the group consisting of —Cl, —Br, —CHF 2 , —CF 3 , —CH 3 and —CN;
R 2 and R 3 are independently selected from the group consisting of hydrogen, an unsubstituted C 1-4 alkyl, an unsubstituted C 1-4 haloalkyl, an optionally substituted C 3-4 cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted aryl(C 1-4 alkyl), an optionally substituted heteroaryl(C 1-4 alkyl) and an optionally substituted heterocyclyl(C 1-4 alkyl);
R 4 and R 5 are independently selected from the group consisting of hydrogen, an unsubstituted C 1-4 alkyl, an unsubstituted C 1-4 haloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted aryl(C 1-4 alkyl), an optionally substituted heteroaryl(C 1-4 alkyl) and an optionally substituted heterocyclyl(C 1-4 alkyl);
R 6 and R 7 are independently selected from the group consisting of hydrogen, an unsubstituted C 1-4 alkyl and an unsubstituted C 1-4 haloalkyl;
R 8 is —CHR 8a R 8b ;
R 8a is hydrogen or —CH 3 ;
R 8b is selected from the group consisting of an unsubstituted C 1-4 alkyl, an unsubstituted C 2-4 alkenyl, an unsubstituted C 2-4 alkynyl, an optionally substituted monocyclic C 3-6 cycloalkyl, an optionally substituted phenyl, an optionally substituted monocyclic heteroaryl and an optionally substituted monocyclic heterocyclyl; and
R 9 is a substituted aryl, an optionally substituted heteroaryl or an optionally substituted heterocyclyl; and
provided that be a compound of Formula (I), or a pharmaceutically acceptable salt thereof, cannot be selected from the group consisting of:

or a pharmaceutically acceptable salt of any of the foregoing.

2. The compound of claim 1 , wherein R 1 is

3. The compound of claim 2 , wherein R 2 is an unsubstituted C 1-4 alkyl; R 3 is hydrogen; R 4 is hydrogen; R 5 is hydrogen; R 6 is hydrogen; and R 7 is hydrogen.

4. The compound of claim 2 , wherein R 2 is hydrogen; R 3 is hydrogen; R 4 is hydrogen; R 5 is hydrogen; R 6 is hydrogen; and R 7 is hydrogen.

5. The compound of claim 3 , wherein the unsubstituted C 1-4 alkyl is methyl.

6. The compound of claim 2 , wherein R 8a is hydrogen.

7. The compound of claim 6 , wherein R 8b is an unsubstituted C 1-4 alkyl.

8. The compound of claim 6 , wherein R 8b is an unsubstituted C 2-4 alkenyl or C 2-4 alkynyl.

9. The compound of claim 6 , wherein R 8b is an optionally substituted monocyclic C 3-6 cycloalkyl, an optionally substituted monocyclic heterocyclyl or an optionally substituted monocyclic heteroaryl.

10. The compound of claim 6 , wherein R 8b is an optionally substituted phenyl.

11. The compound of claim 2 , wherein R 9 is a substituted phenyl.

12. The compound of claim 11 , wherein R 9 is a substituted phenyl, wherein the phenyl is substituted with one or more substituents independently selected from the group consisting of —C(═O)NHCH 3 , halogen, an unsubstituted 5- or 6-membered monocyclic heteroaryl, a 5- or 6-membered monocyclic heteroaryl substituted with a moiety selected from the group consisting of an unsubstituted C 1-4 alkyl and a C 1-4 haloalkyl, an unsubstituted 5- or 6-membered monocyclic heterocyclyl, a 5- or 6-membered monocyclic heterocyclyl substituted with a moiety selected from the group consisting of an unsubstituted C 1-4 alkyl and a C 1-4 haloalkyl.

13. The compound of claim 2 , wherein R 9 is an optionally substituted heteroaryl.

14. The compound of claim 13 , wherein R 9 is an optionally substituted bicyclic heteroaryl.

15. The compound of claim 2 , wherein X is CH.

16. The compound of claim 1 , wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is selected from the group consisting of:

Assignees

• Aligos Therapeutics Inc

Inventors

• Vendeville Sandrine
• Debing Yannick
• Raboisson Pierre Jean-Marie Bernard

Classifications

• C07D471/14 Primary

  Ortho-condensed systems · CPC title

• A61P31/20 Primary

  for DNA viruses · CPC title

• C07D471/16 Primary

  Peri-condensed systems · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title

• A61K31/675

  having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate · CPC title